Q1 Earnings Estimate for Cresco Labs Issued By Roth Capital

Cresco Labs Inc. (OTCMKTS:CRLBF) – Analysts at Roth Capital issued their Q1 2025 EPS estimates for shares of Cresco Labs in a report released on Thursday, March 13th. Roth Capital analyst W. Kirk expects that the company will post earnings per share of ($0.03) for the quarter. The consensus estimate for Cresco Labs’ current full-year earnings is ($0.20) per share. Roth Capital also issued estimates for Cresco Labs’ Q2 2025 earnings at ($0.02) EPS, Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.08) EPS and FY2026 earnings at ($0.04) EPS.

CRLBF has been the topic of several other reports. Atb Cap Markets lowered shares of Cresco Labs from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 9th. Cormark raised shares of Cresco Labs from a “hold” rating to a “moderate buy” rating in a research report on Monday. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $3.00.

Cresco Labs Price Performance

Shares of OTCMKTS:CRLBF opened at $0.71 on Monday. The company’s fifty day moving average price is $0.88 and its 200 day moving average price is $1.19. Cresco Labs has a 12 month low of $0.70 and a 12 month high of $2.60. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.97 and a quick ratio of 1.39. The firm has a market capitalization of $344.14 million, a P/E ratio of -3.53 and a beta of 1.79.

Cresco Labs (OTCMKTS:CRLBF) last announced its quarterly earnings data on Friday, March 14th. The company reported ($0.01) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.01). Cresco Labs had a negative net margin of 9.15% and a negative return on equity of 16.52%. The business had revenue of $176.00 million for the quarter, compared to analyst estimates of $172.10 million.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.